Full-Time
Asset Protection Associate
Updated on 9/3/2026
PharmaCann
501-1,000 employees
Vertical cannabis producer with dispensaries
No salary listed
New Market, MD, USA
In Person
May require minimal travel, long hours, weekends, nights, overtime, holidays, outdoor work, and work during inclement weather.
 Security & Protective Services (1) |
|---|
Get referred to PharmaCann
See people who can refer or advise you
- The candidate must be at least 21 years of age.
- The candidate must have strong interpersonal skills to manage patient, customer, and employee interactions.
- Two to three years of previous asset protection and loss prevention experience in a retail setting are preferred.
- The candidate must have a valid driver's license and successfully pass a Motor Vehicle Record background check.
- The candidate must have a steady employment history.
- The candidate must pass a comprehensive background check that includes criminal history and obtain and maintain state agent requirements.
- The candidate must communicate effectively with employees, customers, and patients.
- The candidate must have strong attention to detail and accurately record information.
- The candidate must be able to handle interactions with irate customers professionally.
- The candidate must be able to escalate employee, patient, or customer issues to the appropriate personnel or management.
- The candidate must be available for long work hours, weekends, nights, overtime as needed, holidays, and open work availability.
- The candidate may need to work outdoors and during inclement weather and lift up to 50 pounds.
- Help drive a positive customer service experience by building relationships, exhibiting empathy, and providing solutions for customer needs.
- Interact with customers and store employees to maintain a safe environment.
- Perform entry and exit control protocols and strict check-in procedures in accordance with state regulations.
- Ensure the safety and security of associates, patients, customers, and vendors on the premises.
- Monitor electronic surveillance and security alarm systems.
- Perform security risk management tasks and manage access control systems.
- Conduct inspections to verify security integrity during and after business hours.
- Patrol internal and external areas.
- Assist with internal and external investigations, including theft and fraud.
- Perform asset protection audits and inventory control functions.
- Review and investigate point-of-sale analytical reports.
- Help ensure operational policies and procedures are followed and professionally greet and register patients, customers, and employees.
- Conduct staff protective security awareness campaigns and promotions.
- Provide assistance as directed during emergencies.
- Perform lockup and unlock duties for designated areas.
- Report security, fire, and safety risks and maintain records of daily activities.
- Monitor traffic and parking on facility property.
- Maintain a clean and organized work area.
- Assist with call center, sales consulting, inventory, outreach, visual merchandising, and delivery acceptance duties as assigned.
- Project a positive image of the organization to employees, customers, industry, and the community.
- Two to three years of previous asset protection and loss prevention experience in a retail setting.
PharmaCann grows, processes, and sells cannabis products across eight states through its own vertically integrated system. It covers the entire supply chain—from cultivation and manufacturing to distributing products in its own dispensaries and through wholesale channels. Products include flower, edibles, tinctures, and topicals, aimed at medical patients and adult consumers who seek wellness and recreation. The company uses its own farms, production facilities, and retail outlets to maintain quality, safety, and consistency, with emphasis on transparent practices and sustainable operations. It differentiates itself by controlling every step of the process (vertical integration), owning dispensaries, maintaining rigorous standards, and investing in facilities and research to ensure affordable, reliable products. PharmaCann’s goal is to provide safe, high-quality cannabis products that improve people’s lives while expanding its market presence and advancing industry standards.
Company Size
501-1,000
Company Stage
Acquired
Total Funding
$206.2M
Headquarters
Oak Park, Illinois
Founded
2014
Get referred to PharmaCann
See people who can refer or advise you
Simplify's Take
What believers are saying
- Grown Rogue's August 21, 2026 deal preserves New York operations and jobs.
- Four New York stores averaged $1.7 million to $2 million monthly sales.
- Up to $15 million in project financing funds restart, inventory, and working capital.
What critics are saying
- Pennsylvania and Denver closures cut 192 jobs in May 2026.
- PharmaCann defaulted on leases; IIPR forced vacating New York, Ohio, and Pennsylvania sites.
- OCM rejection kills the New York platform.
What makes PharmaCann unique
- PharmaCann still controls New York cultivation, manufacturing, and four Verilife dispensaries.
- Its Hamptonburgh site includes 24,000 indoor canopy and 16,000 greenhouse square feet.
- The brand owns scarce multistate licenses across Illinois, Maryland, Massachusetts, Ohio, Pennsylvania.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 12%1 year growth
↑ 12%2 year growth
↑ 12%Cresco Labs acquires nine Pennsylvania dispensaries in accretive Transaction to strengthen market leadership. Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC ("PharmaCann") for an aggregate consideration of US$50 million (the "Transaction"). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing...
Grown Rogue pushes east with planned PharmaCann acquisition. MEDFORD - Grown Rogue International Inc. announced it has taken the first steps toward the planned acquisition of PharmaCann Inc.'s New York license and assets, through the formation of Grown Rogue New York, LLC (GRNY) as a JV with a capital partner. The venture is structured as a 51/49 split and is supported by project-based financing commitments of up to $15 million. The initial agreements include an exclusivity arrangement, along with consulting, lease, and funding contracts intended to prevent significant job losses and an operational shutdown of PharmaCann's New York vertical operations during the interim period before the full transaction closes. Definitive purchase agreements are expected within four weeks, at a preliminary price of approximately $4.5 million. PharmaCann's New York holdings include the Hamptonburgh cultivation and manufacturing facility; approximately 24,000 sq. feet of indoor flower canopy, 16,000 sq. feet of light-deprivation greenhouse capacity, and substantial post-harvest and manufacturing infrastructure. The package also covers four Verilife dispensaries: two combining adult-use and medical sales in the Albany and Syracuse markets, and two medical-only locations in Buffalo and the Bronx. Those stores have averaged aggregate monthly sales of $1.7-$2 million over the past year and a half. PharmaCann, once among the largest privately held cannabis operators in the country, defaulted on lease obligations across properties in New York, Ohio, and Pennsylvania, with a March 2026 settlement with landlord Innovative Industrial Properties (IIPR) mandating the turnover of those facilities by mid-2026. Hamptonburgh production had largely stalled by early 2026 before Grown Rogue stepped in. The capital partner invested $10 million for a 49% preferred equity interest in GRNY, with Grown Rogue retaining a 51% controlling stake. An additional $5 million is accessible through a drawable term loan. During the interim period, GRNY is also extending a secured loan of up to $9 million directly to PharmaCann's New York entity to fund operations, replenish retail inventory, and restart cultivation at Hamptonburgh. Grown Rogue's Chief Strategy Officer Josh Rosen cited New York's potential supply gap [more than 700 licensed dispensaries and limited in-state indoor flower canopy] as central to the thesis, with the company projecting returns on incremental invested capital above 75%. Grown Rogue expects after-tax monthly operating cash flow from the New York assets to reach approximately $600,000 within 18 months. A full close requires regulatory approval from New York's Office of Cannabis Management (OCM). When larger operators exit distressed assets, smaller producers with tight cost discipline tend to pick them up at cents on the dollar. Grown Rogue's entry price against infrastructure that IIPR once backed with $61 million is a clear measure of how far Cannabis asset values have compressed. Project-based financing protects the parent balance sheet - a prudent call given New York's regulatory track record. The real challenge is at Hamptonburgh. Restarting cultivation after a prolonged slowdown, shifting the revenue mix toward adult-use, and maintaining retail continuity across four stores through an ownership transition. Grown Rogue's operational history in Oregon and Michigan suggests the playbook is credible. New York has a reputation for thwarting even well-structured plans, and that remains the key variable here. The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. Highly Capitalized cover capital markets, finance, branding, marketing and everything important in between. Most of all, Highly Capitalized follow the money.
Grown Rogue plans New York entry through PharmaCann license and asset acquisition. August 21, 2026 Grown Rogue International Inc. (CSE: GRIN; OTC: GRUSF) has begun a planned expansion into New York through the proposed acquisition of PharmaCann Inc.'s state cannabis license and assets, establishing a joint venture and up to $15 million in project financing to fund the transaction and restart operations. The proposed acquisition includes PharmaCann's Hamptonburgh cultivation and manufacturing facility and four Verilife dispensaries. The production site has approximately 24,000 square feet of indoor flower canopy, 16,000 square feet of light-deprivation greenhouse flower canopy and substantial manufacturing and post-harvest infrastructure. Grown Rogue formed Grown Rogue New York LLC, or GRNY, as a 51/49 joint venture with a capital partner to execute the expansion. The partner has invested $10 million for a 49% preferred equity interest, while Grown Rogue retains 51%, and has committed an additional $5 million through a drawable term loan. Grown Rogue estimates total acquisition, capital expenditure and working capital requirements at approximately $12 million. The transaction has not yet closed. Grown Rogue and PharmaCann expect to execute definitive purchase agreements within four weeks, with an anticipated purchase price of approximately $4.5 million, including an inventory adjustment. Of that amount, $3 million would be payable after regulatory approval of the proposed change of control. The acquisition remains subject to definitive agreements, regulatory approvals and customary closing conditions. In the meantime, GRNY has begun managing and financing the transition under consulting, lease and funding agreements designed to preserve the operating platform. A secured loan provides PharmaCann's New York operation with up to $9 million to restart Hamptonburgh production, replenish retail inventory and meet working capital requirements. GRNY is also managing the four dispensaries during the interim period. The assets give Grown Rogue immediate production and retail scale in New York if the acquisition is completed. Before substantially reducing production in early 2026, Hamptonburgh produced more than 2,000 pounds of flower per month on average. PharmaCann's four New York dispensaries have generated aggregate monthly sales averaging $1.7 million to $2 million over the past 18 months. The retail portfolio includes adult-use and medical dispensaries in metropolitan Albany and Syracuse and medical-only stores in metropolitan Buffalo and New York City's Bronx. Historically, PharmaCann's New York revenue has been weighted toward medical cannabis, while approximately 80% of wholesale revenue came from flower and pre-roll products. That product mix aligns closely with Grown Rogue's cultivation-focused strategy. The company currently operates in Oregon, Michigan and New Jersey, with expansion underway in Illinois and Minnesota, and specializes in indoor cannabis flower. CEO Obie Strickler said Grown Rogue sees an opportunity in New York because of regulatory changes, enforcement efforts and what the company believes is limited availability of high-quality indoor flower. Chief Strategy Officer Josh Rosen pointed to the state's more than 700 dispensaries and limited in-state indoor flower canopy as factors behind the expansion strategy. The immediate operational priority is restoring production at Hamptonburgh while maintaining the Verilife retail network. Grown Rogue expects the cultivation operation to require six to nine months to ramp and is seeking to retain existing PharmaCann employees while rehiring some former workers. The company also sees substantial restructuring potential in the assets. CFO Andrew Marchington said Grown Rogue has identified cost reductions it expects could lower annual expenses by approximately $20 million during the first six months of oversight. More than 75% of the anticipated savings depend on new and expected adjustments to property and equipment leases. Based on its current operating plan and several assumptions, Grown Rogue projects the New York operations could become after-tax operating cash-flow positive within nine months and generate approximately $600,000 in monthly after-tax operating cash flow within 18 months. Those forecasts depend on factors including lease adjustments, regulatory approvals, financing availability, cultivation ramp-up, market conditions and the company's assumption that Section 280E will no longer apply to the operations by 2027. The project-based financing structure limits the amount of capital Grown Rogue must provide directly while preserving majority ownership of GRNY. The capital partner's preferred equity carries priority distributions and can ultimately be repurchased by Grown Rogue under specified conditions or converted into Grown Rogue subordinate voting shares at predetermined prices over a five-year period. If completed, the PharmaCann transaction would give Grown Rogue a vertically integrated foothold in New York combining cultivation, manufacturing and four existing retail locations. The investment thesis rests on restoring underutilized production capacity, restructuring operating costs and applying Grown Rogue's flower-focused operating model to an established cannabis platform rather than building a New York business from the ground up.
Grown Rogue International has entered an exclusivity agreement to acquire PharmaCann's New York cannabis license and assets through a new entity, Grown Rogue New York. The deal is supported by $15 million in project-based capital commitments. A capital partner invested $10 million for a 49% preferred equity interest in Grown Rogue New York, with Grown Rogue retaining 51%. An additional $5 million is available through a drawable term loan. The anticipated purchase price is approximately $4.5 million. The acquisition includes PharmaCann's Hamptonburgh production facility with 24,000 square feet of indoor flower canopy and four Verilife dispensaries across New York. Grown Rogue expects to reduce annual costs by approximately $20 million and anticipates the New York operations will become cash flow positive within nine months. The company projects monthly after-tax cash flow of around $600,000 within 18 months. The transaction requires definitive purchase agreements and regulatory approval.
PharmaCann Inc. is closing its medical cannabis growing facility in Scott Township, Pennsylvania, on 20 May, resulting in 60 job losses. The company filed a Worker Adjustment and Retraining Notification with the state Department of Labor and Industry last month. The closure affects employees at the 54,000-square-foot facility at 111 Life Science Drive, including technicians, managers and supply chain staff. PharmaCann recently settled a lawsuit with Innovative Industrial Properties related to lease defaults, requiring the company to vacate its Pennsylvania and New York properties by the closure date. Founded in 2014, PharmaCann purchased the 18-acre site in 2018 and received a grower permit from the state Department of Health. The company merged with Colorado-based LivWell Enlightened Health in February.